Journal of Clinical Oncology

One-year access to more than 500 world journals available in the system

Duration of Time : 365 Day
~~Price : 300$~~
Special Price : 100$

Order

Rethinking Success in Pediatric Oncology: Beyond 5-Year Survival

AnnaLynn M. Williams , PhD1; Qi Liu , MSc2; Nickhill Bhakta , MD, MPH1,3; Kevin R. Krull , PhD1,4; Melissa M. Hudson , MD1,5; Leslie L. Robison , PhD1; and Yutaka Yasui , PhD1

doi : 10.1200/JCO.20.03681

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2227-2231

Buy The Package and View The Article Online

Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C)

Noha Sharafeldin , MD, PhD, MSc1; Benjamin Bates , MD2; Qianqian Song , PhD3; Vithal Madhira , MS4; Yao Yan , BS5,6; Sharlene Dong , MS3; Eileen Lee , BSE2; Nathaniel Kuhrt , BS2; Yu Raymond Shao , MD, PhD7; Feifan Liu , PhD8; Timothy Bergquist , PhD6; Justin Guinney , PhD6; Jing Su , PhD9; and Umit Topaloglu , PhD3 on behalf of the National COVID Cohort Collaborative

doi : 10.1200/JCO.21.01074

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2232-2246

Variation in risk of adverse clinical outcomes in patients with cancer and COVID-19 has been reported from relatively small cohorts. The NCATS’ National COVID Cohort Collaborative (N3C) is a centralized data resource representing the largest multicenter cohort of COVID-19 cases and controls nationwide. We aimed to construct and characterize the cancer cohort within N3C and identify risk factors for all-cause mortality from COVID-19.

Buy The Package and View The Article Online

Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

Roisin M. Connolly, MD1; Jeffrey P. Leal, BA1; Lilja Solnes, MD1; Chiung-Yu Huang, PhD1; Ashley Carpenter, MA1; Katy Gaffney, BSN1; Vandana Abramson, MD2; Lisa A. Carey, MD3; Minetta C. Liu, MD4; Mothaffar Rimawi, MD5; Jennifer Specht, MD6; Anna Maria Storniolo, MD7; Vicente Valero, MD8; Christos Vaklavas, MD9; Ian E. Krop, MD, PhD10; Eric P. Winer, MD10; Melissa Camp, MD1; Robert S. Miller, MD1; Antonio C. Wolff, MD1; Ashley Cimino-Mathews, MD1; Ben H. Park, MD, PhD1; Richard L. Wahl, MD11; and Vered Stearns, MD1

doi : 10.1200/JCO.21.00280

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2247-2256

Predictive biomarkers to identify patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer who may benefit from targeted therapy alone are required. We hypothesized that early measurements of tumor maximum standardized uptake value corrected for lean body mass (SULmax) on 18F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) would predict pathologic complete response (pCR) to pertuzumab and trastuzumab (PT).

Buy The Package and View The Article Online

Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma

Anita Kumar , MD1; Carla Casulo , MD2; Ranjana H. Advani , MD3; Elizabeth Budde, MD4; Paul M. Barr , MD2; Connie L. Batlevi , MD, PhD1; Philip Caron, MD1; Louis S. Constine , MD2; Savita V. Dandapani, MD4; Esther Drill , MD1; Pamela Drullinsky, MD1; Jonathan W. Friedberg, MD2; Clare Grieve, BA1; Audrey Hamilton, MD1; Paul A. Hamlin, MD1; Richard T. Hoppe, MD3; Steven M. Horwitz , MD1; Ashlee Joseph, BA1; Niloufer Khan , MD1; Leana Laraque, BA1; Matthew J. Matasar , MD1; Alison J. Moskowitz , MD1; Ariela Noy, MD1; Maria Lia Palomba , MD1; Heiko Sch?der , MD1; David J. Straus, MD1; Shreya Vemuri, BA1; Joanna Yang, MD5; Anas Younes , MD6; Andrew D. Zelenetz , MD, PhD1; Joachim Yahalom , MD1; and Craig H. Moskowitz, MD7

doi : 10.1200/JCO.21.00108

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2257-2265

To improve curability and limit long-term adverse effects for newly diagnosed early-stage (ES), unfavorable-risk Hodgkin lymphoma.

Buy The Package and View The Article Online

Impact of Risk-Adapted Therapy for Pediatric Hodgkin Lymphoma on Risk of Long-Term Morbidity: A Report From the Childhood Cancer Survivor Study

Kevin C. Oeffinger, MD1; Kayla L. Stratton, MS2; Melissa M. Hudson, MD3; Wendy M. Leisenring, ScD2; Tara O. Henderson, MD, MPH4; Rebecca M. Howell, PhD5; Suzanne L. Wolden, MD6; Louis S. Constine, MD7; Lisa R. Diller, MD8; Charles A. Sklar, MD6; Paul C. Nathan, MD, MSc9; Sharon M. Castellino, MD, MSc10; Dana Barnea, MD11; Susan A. Smith, MPH5; Raymond J. Hutchinson, MD, MS12; Gregory T. Armstrong, MD, MSCE3; and Leslie L. Robison, PhD3

doi : 10.1200/JCO.20.01186

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2266-2275

To determine the incidence of serious chronic health conditions among survivors of pediatric Hodgkin lymphoma (HL), compare by era of therapy and by selected cancer therapies, and provide estimates of risks associated with contemporary therapy.

Buy The Package and View The Article Online

Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation

Monika L. Metzger, MD, MS1,2; Michael P. Link, MD3; Amy L. Billett, MD4; Jamie Flerlage, MD1,2; John T. Lucas Jr, MD, MS5; Belinda N. Mandrell, PhD6; Matthew J. Ehrhardt, MD, MS1,2; Nickhill Bhakta, MD1,2; Torunn I. Yock, MD7; Alison M. Friedmann, MD, MS8; Pedro de Alarcon, MD9; Sandra Luna-Fineman, MD10; Eric Larsen, MD11; Sue C. Kaste, DO1,12,13; Barry Shulkin, MD12; Zhaohua Lu, PhD14; Chen Li, MS14; Susan M. Hiniker, MD15; Sarah S. Donaldson, MD15; Melissa M. Hudson, MD1,2; and Matthew J. Krasin, MD5

doi : 10.1200/JCO.20.03286

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2276-2283

Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL.

Buy The Package and View The Article Online

Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death

Derya Tilki, MD1,2; Ming-Hui Chen , PhD3; Jing Wu, PhD4; Hartwig Huland, MD1; Markus Graefen, MD1; Thomas Wiegel, MD5; Dirk B?hmer , MD6; Osama Mohamad, MD, PhD7; Janet E. Cowan , MA8; Felix Y. Feng, MD7,8; Peter R. Carroll , MD, MPH8; Bruce J. Trock , MPH, PhD9; Alan W. Partin, MD, PhD10; and Anthony V. D'Amico , MD, PhD11

doi : 10.1200/JCO.20.03714

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2284-2293

Adjuvant compared with early salvage radiation therapy (sRT) following radical prostatectomy (RP) has not been shown to reduce progression-free survival in randomized controlled trials. However, these trials might have missed a benefit in men with adverse pathology at RP given that these men were under-represented and immortal time bias might have been present; herein, we investigate this possibility.

Buy The Package and View The Article Online

Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Kim N. Chi , MD1; Simon Chowdhury, MD, PhD2; Anders Bjartell , MD, PhD3; Byung Ha Chung , MD, PhD4; Andrea J. Pereira de Santana Gomes , MD5; Robert Given, MD6; Alvaro Ju?rez Soto, MD7; Axel S. Merseburger, MD, PhD8; Mustafa ?zgüro?lu , MD9; Hirotsugu Uemura, MD, PhD10; Dingwei Ye , MD, PhD11; Sabine Brookman-May, MD12,13; Suneel D. Mundle , PhD13; Sharon A. McCarthy, BPharm13; Julie S. Larsen, PharmD14; Weili Sun, MD, PhD14; Katherine B. Bevans , PhD15; Ke Zhang , PhD16; Nibedita Bandyopadhyay, PhD13; and Neeraj Agarwal , MD17

doi : 10.1200/JCO.20.03488

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2294-2303

The first interim analysis of the phase III, randomized, placebo-controlled TITAN study showed that apalutamide significantly improved overall survival (OS) and radiographic progression-free survival in patients with metastatic castration-sensitive prostate cancer (mCSPC) receiving ongoing androgen deprivation therapy (ADT). Herein, we report final efficacy and safety results after unblinding and placebo-to-apalutamide crossover.

Buy The Package and View The Article Online

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Jaume Capdevila, MD, PhD1; Nicola Fazio, MD, PhD2; Carlos Lopez, MD, PhD3; Alexandre Teulé, MD4; Juan W. Valle, MD5; Salvatore Tafuto, MD6; Ana Custodio, MD7; Nicholas Reed, MD8; Markus Raderer, MD9; Enrique Grande, MD, PhD10; Rocio Garcia-Carbonero, MD11; Paula Jimenez-Fonseca, MD12; Jorge Hernando, MD, PhD1; Alberto Bongiovanni, MD13; Francesca Spada, MD, PhD2; Vicente Alonso, MD, PhD14; Lorenzo Antonuzzo, MD, PhD15; Andrea Spallanzani, MD16; Alfredo Berruti, MD17; Adelaida La Casta, MD18; Isabel Sevilla, MD19; Patrizia Kump, MD, PhD20; Dario Giuffrida, MD21; Xavier Merino, MD1; Lorena Trejo, MD, PhD1; Pablo Gajate, MD, PhD22; Ignacio Matos, MD, PhD1; Angela Lamarca, MD, PhD5; and Toni Ibrahim, MD13

doi : 10.1200/JCO.20.03368

Journal of Clinical Oncology 39, no. 20 (July 10, 2021) 2304-2312

Approved systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have shown limited capacity to reduce tumor burden and no antitumor activity after progression to targeted agents (TAs). We investigated the efficacy and safety of lenvatinib in patients with previously treated advanced GEP-NETs.

Buy The Package and View The Article Online